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Background
Vaccibodies are recombinant molecules that can elicit
strong CD4+ T lymphocyte and antibody responses and
have shown promising results in treatment of B lympho-
mas and multiple myelomas in mice. The vaccibody is a
bivalent homodimer and consists of three functional
units; an N-terminal targeting unit, a dimerization unit
and a C-terminal antigenic unit. In order to elucidate
whether such molecules could be exploited in vaccination
against HIV, we inserted gp120 in the antigenic unit. Fur-
thermore, two molecules were tested for their targeting
properties: i) the chemokine MIP-1alpha (CCL3) and, ii)
V regions that specifically bind MHC class II. Mutated
murine MIP-1alpha (mMIP-1alphaC11S) unable to bind
its receptors and non-targeted control specific for NIP,
were included as negative controls.
Methods
The vaccibody constructs in the form of 50 microgram
DNA were injected into the quadriceps of BALB/c mice. In
some experiments, the muscle was exposed to electropo-
ration after injection. Cellular immune responses were
measured by Dd/P18 tetramer binding and by IFN-
gamma-ELISPOT and humoral responses by ELISA.
Results
The vaccibody containing murine MIP-1alpha linked to
gp120 enhanced the antigen-specific CD8+ T lymphocyte
response approx. 5-fold compared to non-targeted control
or gp120 alone and also elicited the strongest T lym-
phocyte memory response. Moreover, physical linkage
between mMIP-1alpha and gp120 elicited a more sustain-
able cellular response than mMIP-1alpha and gp120
administered in separate plasmids. Targeting to MHC
class II induced the highest titer of gp120-specific anti-
bodies.
Conclusion
Taken together, our data show that the targeted gp120-
containing vaccibodies are more immunogenic than
gp120 alone. Moreover, our data suggest that MIP-1alpha
can mediate delivery to the MHC class I pathway and pro-
mote cross-presentation to CD8+ T lymphocytes. As the
human and murine MIP-1alpha show similar receptor
binding, MIP1alpha-targeted vaccibodies might be a help-
ful tool in increasing the immunogenicity of vaccines
towards HIV.
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